Thromboangiitis Obliterans

01Pathophysiology

Thromboangitis obliterans is a non-atherosclerotic inflammatory vasculopathy that selectively targets small and medium-sized arteries and veins of the upper and lower extremities. Unlike atherosclerosis, the disease involves segments of vessels in a "skip lesion" pattern, leaving the proximal large arteries entirely normal. This distinction is critical and frequently tested.

The disease is driven by tobacco exposure, though the exact immunologic trigger remains incompletely defined. Current evidence points to an aberrant immune response in genetically susceptible individuals. Tobacco glycoproteins act as antigens that provoke an inflammatory cascade within the vessel wall and lumen. This leads to a highly cellular, inflammatory thrombus that is the hallmark of the disease. Importantly, the thrombus contains polymorphonuclear leukocytes, microabscesses, and occasionally multinucleated giant cells, distinguishing it from the bland, platelet-fibrin thrombi seen in atherosclerotic disease.

A critical pathologic feature is that the internal elastic lamina remains intact. This means the vessel wall architecture is preserved even as the lumen is occluded by inflammatory thrombus. This stands in contrast to vasculitides like polyarteritis nodosa, which cause fibrinoid necrosis and destruction of the vessel wall.

Because the disease targets distal arteries (below the knee and below the elbow), ischemia appears first in the most distal tissues: the fingertips, toes, and foot arch. This is why patients present with instep claudication (pain in the arch of the foot with walking) rather than the calf claudication typical of atherosclerotic peripheral artery disease. Rest pain, digital ulceration, and eventual gangrene occur when collateral circulation cannot compensate for the progressive occlusion.

The venous component of the disease produces migratory superficial thrombophlebitis, which appears as tender, erythematous, cordlike nodules along superficial veins. This finding, combined with distal arterial insufficiency in a young smoker, is essentially pathognomonic and appears frequently in exam vignettes as the defining clue.

Raynaud phenomenon occurs because the inflammatory process and distal occlusion impair vasomotor regulation of digital arteries. The classic triphasic color change (white, blue, red) in the fingers or toes reflects vasospasm superimposed on a fixed occlusive process.

02Classification and Clinical Manifestation

Clinical Phases by Pathology

Clinical Manifestation by Vascular Bed

Shionoya Diagnostic Criteria (All Five Must Be Present)

The exam commonly tests your ability to recognize that this disease involves both upper and lower extremities and both arteries and veins. Atherosclerosis almost never affects the upper extremities in a young patient, so upper limb ischemia in a smoker under 45 should immediately raise this diagnosis.

03Diagnostic Workup

The best initial diagnostic step is clinical recognition using established criteria (Shionoya or Olin). The diagnosis is fundamentally clinical. When a vignette presents a male patient under age 45 with a heavy smoking history, distal extremity ischemia, and no traditional atherosclerotic risk factors, Buerger disease should be your leading diagnosis before any test is ordered.

The Allen test is a bedside maneuver that evaluates the patency of the radial and ulnar arteries feeding the palmar arch. The examiner compresses both arteries while the patient makes a fist, then releases one artery at a time. Normally, the hand flushes pink within a few seconds. In Buerger disease, refill is delayed or absent because the distal arteries are occluded. An abnormal Allen test in a young smoker with digital ischemia is a frequently tested combination.

Non-invasive vascular studies (ABI, segmental pressures, pulse volume recordings) should be obtained early to document the level and severity of occlusion. The ABI will be reduced, and segmental pressure measurements will demonstrate a pressure gradient that drops at the distal (ankle or wrist) level while remaining normal proximally.

The most accurate and confirmatory test is angiography (either CT angiography or conventional catheter-based angiography). The characteristic angiographic findings are:

1. Segmental occlusion of small and medium distal arteries (tibial, peroneal, radial, ulnar, palmar, and plantar arteries)

2. "Corkscrew" or "tree root" collateral vessels bridging the occluded segments

3. Normal proximal arteries (aorta, iliac, femoral, brachial) with no evidence of atherosclerotic plaque

This angiographic pattern is the imaging finding you will be asked to identify on the exam. The combination of distal disease with corkscrew collaterals and clean proximal vessels is essentially diagnostic.

Laboratory testing is performed to exclude mimics, not to confirm Buerger disease. There is no laboratory marker for this condition. You order an autoimmune panel (ANA, RF, antiphospholipid antibodies, complement levels), a metabolic panel (glucose, HbA1c, lipids), and inflammatory markers (ESR, CRP). All of these should be normal or negative. If any autoimmune marker is positive, reconsider the diagnosis and think about conditions like scleroderma, lupus, or antiphospholipid syndrome.

Echocardiography is ordered to exclude a cardiac embolic source (vegetations, thrombus, patent foramen ovale) as a cause of distal ischemia.

Biopsy is almost never required in clinical practice or on exams, but if performed, it shows the characteristic inflammatory thrombus with microabscesses and an intact internal elastic lamina. It may appear in a question asking what histologic finding differentiates Buerger disease from polyarteritis nodosa (where you would see fibrinoid necrosis and vessel wall destruction).

04Management and Treatment

Step 1: Absolute Tobacco Cessation

This is the single most important and most tested point. No other therapy is effective if the patient continues to smoke. Disease progression, including the development of gangrene requiring amputation, occurs almost exclusively in patients who continue tobacco use. Conversely, patients who achieve complete cessation rarely require amputation. The exam may present a patient who has undergone all appropriate treatments but continues to deteriorate, and the answer is that the patient has not stopped smoking.

Complete cessation means all tobacco products: cigarettes, cigars, pipes, chewing tobacco, and hookah. There is evidence that even nicotine replacement therapy (patches, gum) may perpetuate the disease, so some experts recommend avoiding nicotine-containing cessation aids and using non-nicotine agents like varenicline (1 mg twice daily for 12 weeks) or bupropion (150 mg twice daily for 7 to 12 weeks) instead.

Step 2: Pharmacologic Therapy for Critical Limb Ischemia

For patients presenting with rest pain or ischemic ulcers (critical limb ischemia), iloprost is the best-studied pharmacologic agent. Iloprost is a synthetic prostacyclin (PGI2) analog that promotes vasodilation and inhibits platelet aggregation. It is administered as an intravenous infusion at 0.5 to 2.0 ng/kg/min over 6 hours daily for a course of 21 to 28 days. Studies have shown that iloprost significantly improves rest pain and promotes ulcer healing compared to placebo in patients with Buerger disease.

Step 3: Symptomatic Management

For Raynaud phenomenon and vasospasm, calcium channel blockers (nifedipine 30 to 60 mg daily) reduce the frequency and severity of vasospastic episodes. For claudication symptoms, cilostazol (100 mg twice daily, taken 30 minutes before or 2 hours after meals) may improve walking distance. Cilostazol is contraindicated in patients with heart failure. Low-dose aspirin (75 to 100 mg daily) is generally prescribed for its antiplatelet effect, though direct evidence in Buerger disease is limited.

Step 4: Interventional and Surgical Options

Surgical bypass and endovascular revascularization are generally not feasible in Buerger disease because the target vessels (distal small arteries) are too small and diffusely diseased for reconstruction. This is a key distinction from atherosclerotic PAD, where bypass grafting and angioplasty are standard interventions. The exam may test this by offering bypass surgery as a tempting answer choice for a Buerger patient with critical ischemia.

Sympathectomy (lumbar for lower extremity, cervical for upper extremity) may be considered in patients with persistent rest pain or non-healing ulcers despite maximal medical therapy and smoking cessation. Sympathectomy reduces vasomotor tone and may improve blood flow to ischemic tissues, but the evidence for long-term benefit is inconsistent.

Amputation is reserved for irreversible gangrene or severe secondary infection. The goal is to amputate at the most distal viable level to preserve as much functional tissue as possible. The exam may present this as the "next best step" when a patient has established gangrene with signs of secondary infection despite having stopped smoking.

Contraindications to Note:

• Cilostazol is contraindicated in heart failure (increases mortality in CHF through phosphodiesterase-3 inhibition).

• Nicotine replacement therapy is relatively contraindicated because nicotine itself may sustain the disease process.

• Revascularization surgery is generally not an option due to diffuse distal vessel involvement.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students get questions on Buerger disease wrong is by confusing it with atherosclerotic peripheral artery disease. Both conditions cause limb ischemia in smokers, and both are associated with reduced distal pulses. The critical discriminators are the patient's age (under 45 for Buerger), the absence of other atherosclerotic risk factors (no diabetes, no hyperlipidemia, no hypertension), and the location of vessel involvement (distal for Buerger, proximal for atherosclerosis). If the vignette describes a 55-year-old diabetic smoker with calf claudication, that is atherosclerotic PAD. If the vignette describes a 32-year-old smoker with no other risk factors and foot arch pain, that is Buerger disease.

The second major trap involves management. Students frequently choose surgical bypass or angioplasty for a patient with Buerger disease who has worsening ischemia. Revascularization is almost never feasible because the disease involves small distal arteries that cannot serve as surgical targets. The correct answer for a Buerger patient with progressive disease is nearly always tobacco cessation (if still smoking) or iloprost (if critical ischemia is present and the patient has already stopped smoking).

A third tested concept is the migratory superficial thrombophlebitis. This finding, appearing as tender erythematous cords along superficial veins that migrate over time, strongly suggests Buerger disease when seen alongside distal arterial insufficiency. Students may confuse this with deep vein thrombosis or Trousseau syndrome (migratory thrombophlebitis associated with occult malignancy). The distinction is that Trousseau syndrome occurs in older patients, often with weight loss and other constitutional symptoms pointing to an underlying cancer, while Buerger disease occurs in young smokers with concurrent arterial findings.

Finally, remember that the Allen test is a high-yield bedside finding. In a vignette describing a young smoker with digital ischemia and an abnormal Allen test, the exam is asking you to recognize Buerger disease. The Allen test is rarely mentioned in the context of other diagnoses and functions as a strong buzzword.

The core competency being tested is your ability to identify a young, otherwise healthy smoker with distal extremity ischemia and to recognize that this presentation, along with migratory thrombophlebitis and corkscrew collaterals on angiography, points to Buerger disease rather than atherosclerotic PAD or systemic vasculitis. The management takeaway is that tobacco cessation is the treatment, and that failure to stop smoking is the primary driver of disease progression and amputation.